Printer Friendly

Hansa Medical announces receipt of orphan drug designation from US FDA for IdeS to treat Guillain-BarrA(c) syndrome.

M2 EQUITYBITES-February 19, 2018-Hansa Medical announces receipt of orphan drug designation from US FDA for IdeS to treat Guillain-BarrA(c) syndrome

(C)2018 M2 COMMUNICATIONS http://www.m2.com

Biopharmaceutical company Hansa Medical AB (STO:HMED) announced on Friday the grant by the US Food and Drug Administration (FDA) of orphan drug designation (ODD) to IdeS for the treatment of Guillain-Barre syndrome (GBS).

According to the company, it is now planning a phase II study in GBS with IdeS, an IgG-degrading enzyme of Streptococcus pyogenes that depletes IgG antibodies fast and effectively.

Guillain Barre syndrome (GBS) is an acute autoimmune disease in which the peripheral nervous system is attacked by the immune system and IgG-antibodies.

Hansa Medical is developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead product, IdeS, is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Feb 19, 2018
Words:173
Previous Article:Instalco Intressenter posts increased EPS in 2017.
Next Article:Cancer Research UK plans major investment in clinical trial unit network.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters